Status:
COMPLETED
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
Lead Sponsor:
McMaster University
Collaborating Sponsors:
The Physicians' Services Incorporated Foundation
Conditions:
Clostridium Enterocolitis
Antibiotic-Associated Diarrhea
Eligibility:
All Genders
14+ years
Phase:
PHASE3
Brief Summary
What is the difference between the use of one drug (Oral Metronidazole) versus the use of this same drug combined with another drug (Rifampin) in treatment of bacteria and infection-associated diarrhe...
Detailed Description
Clostridium difficile infection contributes to both community and hospital acquired morbidity and mortality. Metronidazole alone is usually considered the drug of choice, however, frequent relapses oc...
Eligibility Criteria
Inclusion
- Inpatients + outpatients diagnosed with CDAD based on SHEA definition \[Laboratory confirmation for presence of C.difficile toxin using enzyme immunoassay and no other etiology for diarrhea + Presence of 1 or more of the following: diarrhea (6 watery stool over 36 hours or 3 unformed stools in 24 hours for at least 2days), pseudomembranes at endoscopy\].
Exclusion
- Age \< 14 yr
- Known hypersensitivity to metronidazole, rifampin
- Receiving medication(s) with potential significant drug interaction with rifampin
- Active liver disease as indicated by ALT \> 200 U/L
- Adynamic ileus
- Toxic megacolon
- Pregnancy
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 31 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00182429
Start Date
February 1 2004
End Date
December 31 2005
Last Update
August 15 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton General Hospital
Hamilton, Ontario, Canada, L8L 2X2
2
McMaster University Medical Centre
Hamilton, Ontario, Canada, L8N 3Z5
3
St. Joseph's Healthcare
Hamilton, Ontario, Canada, L8N 4A6
4
Henderson General Hospital
Hamilton, Ontario, Canada, L8V 1C3